Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock: What Does the Chart Say Thursday?

Overall market sentiment has been down on Sonnet BioTherapeutics Holdings, Inc. (SONN) stock lately. SONN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sonnet BioTherapeutics Holdings, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SONN!

See Full SONN Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SONN Stock Today?

Sonnet BioTherapeutics Holdings, Inc. (SONN) stock is trading at $1.15 as of 12:53 PM on Thursday, Oct 26, a loss of -$0.14, or -10.86% from the previous closing price of $1.29. The stock has traded between $1.08 and $1.32 so far today. Volume today is more active than usual. So far 112,805 shares have traded compared to average volume of 60,371 shares. To see InvestorsObserver's Sentiment Score for Sonnet BioTherapeutics Holdings, Inc. click here.

More About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Click Here to get the full Stock Report for Sonnet BioTherapeutics Holdings, Inc. stock.